Jonathan A Ledermann (Jonathan Ledermann)

ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 28

Top Topics

Endometrial Cancer

Clinical Practice

Acute Lymphoblastic Leukemia

Top Venues

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Therapeutic advances in medical oncology

OncoTargets and therapy

This page only lists publications with an associated author ORCID identifier.

Publications

Eve Merry, Ronas Taner Kesmez, Tamara Yu, Michael Flynn, Jonathan A Ledermann, Michelle Lockley, Nicola Macdonald, Mary McCormack, Shibani Nicum, Shanthini Crusz, Rowan E Miller
A multicenter retrospective study to assess feasibility, safety and efficacy of first-line carboplatin-paclitaxel versus carboplatin monotherapy in a frail, elderly epithelial ovarian cancer population. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2024)
Agnieszka Michael, William Wilson, Sunny Sunshine, Nicola Annels, Richard Harrop, Daniel Blount, Hardev Pandha, Rosemary Lord, Yen Ngai, Shibani Nicum, Laura Stylianou, Stephen Gwyther, Iain A McNeish, Allan Hackshaw, Jonathan A Ledermann
A randomized phase II trial to examine modified vaccinia Ankara-5T4 vaccine in patients with relapsed asymptomatic ovarian cancer (TRIOC). International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2024)
Angelina Tjokrowidjaja, Michael L Friedlander, Jonathan A Ledermann, Robert L Coleman, Mansoor Raza Mirza, Ursula A Matulonis, Eric Pujade-Lauraine, Sarah Sally J Lord, Clare L Scott, Sandra Goble, Whitney York, Chee Khoon Lee, null null
Poor Concordance Between Cancer Antigen-125 and RECIST Assessment for Progression in Patients With Platinum-Sensitive Relapsed Ovarian Cancer on Maintenance Therapy With a Poly(ADP-ribose) Polymerase Inhibitor. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (11) (2024)
Angelina Tjokrowidjaja, Michael L Friedlander, Jonathan A Ledermann, Robert L Coleman, Mansoor Raza Mirza, Ursula A Matulonis, Eric Pujade-Lauraine, Sarah Sally J Lord, Clare L Scott, Sandra Goble, Whitney York, Chee Khoon Lee, null null
Poor Concordance Between Cancer Antigen-125 and RECIST Assessment for Progression in Patients With Platinum-Sensitive Relapsed Ovarian Cancer on Maintenance Therapy With a Poly(ADP-ribose) Polymerase Inhibitor. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Angelina Tjokrowidjaja, Michael L Friedlander, Jonathan A Ledermann, Robert L Coleman, Mansoor Raza Mirza, Ursula A Matulonis, Eric Pujade-Lauraine, Sarah Sally J Lord, Clare L Scott, Sandra Goble, Whitney York, Chee Khoon Lee, null null
Poor Concordance Between Cancer Antigen-125 and RECIST Assessment for Progression in Patients With Platinum-Sensitive Relapsed Ovarian Cancer on Maintenance Therapy With a Poly(ADP-ribose) Polymerase Inhibitor. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (11) (2024)
Agnieszka Michael, William Wilson, Sunny Sunshine, Nicola Annels, Richard Harrop, Daniel Blount, Hardev Pandha, Rosemary Lord, Yen Ngai, Shibani Nicum, Laura Stylianou, Stephen Gwyther, Iain A McNeish, Allan Hackshaw, Jonathan A Ledermann
A randomized phase II trial to examine modified vaccinia Ankara-5T4 vaccine in patients with relapsed asymptomatic ovarian cancer (TRIOC). International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 34 (8) (2024)
Aleksandra Helena Symonides, Nicolò Bizzarri, Martina Aida Angeles, Charalampos Theofanakis, Alexander B Shushkevich, Aleksandra Natalia Strojna, Andrei Pletnev, Tanja Nikolova, Jonathan A Ledermann, Ignace Vergote
Best original research presented at the 23rd European Congress on Gynaecological Oncology-Best of ESGO 2022. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 33 (2) (2023)
Rebecca C Arend, Bradley J Monk, Ronnie Shapira-Frommer, Ashley F Haggerty, Edwin A Alvarez, Amnon Amit, Angeles A Secord, Carolyn Muller, Antonio Casado Herraez, Thomas J Herzog, Krishnansu S Tewari, Joshua G Cohen, Marilyn Huang, Adelya Yachnin, Laura L Holeman, Jonathan A Ledermann, Tamar Rachmilewitz Minei, Marc E Buyse, Shifra Fain Shmueli, Michal Lavi, Dror Harats, Richard T Penson, null null
Ofranergene Obadenovec (Ofra-Vec, VB-111) With Weekly Paclitaxel for Platinum-Resistant Ovarian Cancer: Randomized Controlled Phase III Trial (OVAL Study/GOG 3018). Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Aleksandra Helena Symonides, Nicolò Bizzarri, Martina Aida Angeles, Charalampos Theofanakis, Alexander B Shushkevich, Aleksandra Natalia Strojna, Andrei Pletnev, Tanja Nikolova, Jonathan A Ledermann, Ignace Vergote
Best original research presented at the 23rd European Congress on Gynaecological Oncology-Best of ESGO 2022. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 33 (2) (2023)
Ingrid A Boere, Ignace Vergote, Rob Hanssen, Mathilde Jalving, Christine Gennigens, Petronella Ottevanger, Yes J van de Wouw, Cristianne J F Rijcken, Ron H J Mathijssen, Jonathan A Ledermann
CINOVA: a phase II study of CPC634 (nanoparticulate docetaxel) in patients with platinum resistant recurrent ovarian cancer. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2023)
Gabriel Levin, Ross Harrison, Jonathan A Ledermann, Raanan Meyer, Robert L Coleman, Pedro T Ramirez
Evaluating open access publication and research impact in gynecologic oncology. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2023)
Thomas Gaillard, Schwameis Richard, Enora Laas-Faron, Tali Eisenberg-Nissim, Xavier Matias-Guiu, Carien L Creutzberg, Jonathan A Ledermann, François Planchamp, Nicole Concin
An easy, fast, and accurate way for implementing the standards of care for the management of patients with endometrial carcinoma into daily clinical practice: the ESGO mobile app. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2023)
Ellen Nuttall Musson, Rowan E Miller, Marc R Mansour, Michelle Lockley, Jonathan A Ledermann, Elspeth M Payne
Monitoring clone dynamics and reversibility in clonal haematopoiesis and myelodysplastic neoplasm associated with PARP inhibitor therapy-a role for early monitoring and intervention. Leukemia (2023)
Aleksandra Helena Symonides, Nicolò Bizzarri, Martina Aida Angeles, Charalampos Theofanakis, Alexander B Shushkevich, Aleksandra Natalia Strojna, Andrei Pletnev, Tanja Nikolova, Jonathan A Ledermann, Ignace Vergote
Best original research presented at the 23rd European Congress on Gynaecological Oncology-Best of ESGO 2022. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 33 (2) (2023)
Aleksandra Helena Symonides, Nicolò Bizzarri, Martina Aida Angeles, Charalampos Theofanakis, Alexander B Shushkevich, Aleksandra Natalia Strojna, Andrei Pletnev, Tanja Nikolova, Jonathan A Ledermann, Ignace Vergote
Best original research presented at the 23rd European Congress on Gynaecological Oncology-Best of ESGO 2022. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2022)
Yeh Chen Lee, Madeleine T King, Rachel L O'Connell, Anne Lanceley, Florence Joly, Felix Hilpert, Alison Davis, Felicia T Roncolato, Aikou Okamoto, Jane Bryce, Paul Donnellan, Amit M Oza, Elisabeth Avall-Lundqvist, Jonathan S Berek, Jonathan A Ledermann, Dominique Berton, Jalid Sehouli, Amanda Feeney, Marie-Christine Kaminsky, Katrina Diamante, Martin R Stockler, Michael L Friedlander, null null
Symptom burden and quality of life with chemotherapy for recurrent ovarian cancer: the Gynecologic Cancer InterGroup-Symptom Benefit Study. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 32 (6) (2022)
Domenico Pagano, Philip Home, Alar Irs, Jonathan A Ledermann, Giuseppe Curigliano, Tsuguo Iwatani, John Mandrola, Nick Freemantle
The path for medical associations to sponsor trustworthy guidelines: is it feasible? Journal of the Royal Society of Medicine 115 (7) (2022)
Rowan E Miller, Osnat Elyashiv, Karim Hussien El-Shakankery, Jonathan A Ledermann
Ovarian Cancer Therapy: Homologous Recombination Deficiency as a Predictive Biomarker of Response to PARP Inhibitors. OncoTargets and therapy 15 (2022)
Martina Aida Angeles, Felix Boria Alegre, Alexander B Shushkevich, Nicolò Bizzarri, Charalampos Theofanakis, Gabriella Schivardi, Aleksandra Helena Symonides, Aleksandra Natalia Strojna, Esra Bilir, Sven Mahner, Murat Gultekin, David Cibula, Alexandros Rodolakis, Domenica Lorusso, Mansoor Raza Mirza, Anna Fagotti, Jonathan A Ledermann, Christina Fotopoulou, Pedro T Ramirez
Interviews conducted at the European Society of Gynaecological Oncology 2022 Congress: a ENYGO-IJGC Fellows initiative. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2022)
Osnat Elyashiv, Yien Ning Sophia Wong, Jonathan A Ledermann
Frontline Maintenance Treatment for Ovarian Cancer. Current oncology reports 23 (8) (2021)
Alexandra Taylor, Sudha S Sundar, Rebecca Bowen, Rick Clayton, Sarah Coleridge, Christina Fotopoulou, Sadaf Ghaem-Maghami, Jonathan A Ledermann, Ranjit Manchanda, Hilary Maxwell, Agnieszka Michael, Tracie Miles, Shibani Nicum, Andrew Nordin, Bruce Ramsay, Stuart Rundle, Sarah Williams, Nicholas J Wood, Dennis Yiannakis, Jo Morrison
British Gynaecological Cancer Society recommendations for women with gynecological cancer who received non-standard care during the COVID-19 pandemic. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2021)
Andrew R Clamp, Domenica Lorusso, Amit M Oza, Carol Aghajanian, Ana Oaknin, Andrew Dean, Nicoletta Colombo, Johanne I Weberpals, Giovanni Scambia, Alexandra Leary, Robert W Holloway, Margarita Amenedo Gancedo, Peter C Fong, Jeffrey C Goh, David M O'Malley, Deborah K Armstrong, Susana Banerjee, Jesus García-Donas, Elizabeth M Swisher, Terri Cameron, Sandra Goble, Robert L Coleman, Jonathan A Ledermann
Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 31 (7) (2021)
Alexandra Leary, David Tan, Jonathan A Ledermann
Immune checkpoint inhibitors in ovarian cancer: where do we stand? Therapeutic advances in medical oncology 13 (2021)
Amit M Oza, Domenica Lorusso, Carol Aghajanian, Ana Oaknin, Andrew Dean, Nicoletta Colombo, Johanne I Weberpals, Andrew R Clamp, Giovanni Scambia, Alexandra Leary, Robert W Holloway, Margarita Amenedo Gancedo, Peter C Fong, Jeffrey C Goh, David M O'Malley, Deborah K Armstrong, Susana Banerjee, Jesús García-Donas, Elizabeth M Swisher, David Cella, Juliette Meunier, Sandra Goble, Terri Cameron, Lara Maloney, Ann-Christin Mörk, Josh Bedel, Jonathan A Ledermann, Robert L Coleman
Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian Carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 38 (30) (2020)
Osnat Elyashiv, Jonathan A Ledermann, Gita Parmar, Laura Farrelly, Nicholas Counsell, Amanda Feeney, Fatima El-Khouly, Ian Macdonald, Andreia Neto, Esther Arthur-Darkwa, Eva Burnett, Gordon C Jayson, Linda Mileshkin, Charlie Gourley, Shibani Nicum
ICON 9-an international phase III randomized study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 31 (1) (2020)
Nicole Concin, Xavier Matias-Guiu, Ignace Vergote, David Cibula, Mansoor Raza Mirza, Simone Marnitz, Jonathan A Ledermann, Tjalling Bosse, Cyrus Chargari, Anna Fagotti, Christina Fotopoulou, Antonio Gonzalez Martin, Sigurd Lax, Domenica Lorusso, Christian Marth, Philippe Morice, Remi A Nout, Dearbhaile O'Donnell, Denis Querleu, Maria Rosaria Raspollini, Jalid Sehouli, Alina Sturdza, Alexandra Taylor, Anneke Westermann, Pauline Wimberger, Nicoletta Colombo, François Planchamp, Carien L Creutzberg
ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 31 (1) (2020)
Jonathan A Ledermann, Eric Pujade-Lauraine
Olaparib as maintenance treatment for patients with platinum-sensitive relapsed ovarian cancer. Therapeutic advances in medical oncology 11 (2019)
Jonathan A Ledermann
First-line treatment of ovarian cancer: questions and controversies to address. Therapeutic advances in medical oncology 10 (2018)